BMRN

$57.132.64%1.47

After Hours: 57.01-0.12 -0.21%

Biomarin Pharmaceutical Inc (BMRN)

Date: O: H: L: C: Vol:

Biomarin Pharmaceutical Inc stock is traded at $57.13, with a volume of 2,844,764. It is up +2.64% in the last 24 hours and down -0.09% over the past month. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Previous Close:

$55.66

Open:

$56.60

24h Volume:

2,844,764

Relative Volume:

1.07

Market Cap:

$11.06B

Revenue:

$3.29B

Net Income/Loss:

$268.74M

P/E Ratio:

41.69

EPS:

$1.37

Net Cash Flow:

$759.12M

1W Performance:

+2.02%

1M Performance:

-0.09%

6M Performance:

+3.01%

1Y Performance:

+8.78%

1-Day Range:

$55.67$57.51

1-Week Range:

$52.00$59.51

52-Week Range:

$49.26$70.98

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name

Biomarin Pharmaceutical Inc

Sector

Healthcare

Industry

Biotechnology

Phone

(415) 506-6700

Address

105 DIGITAL DRIVE, NOVATO, CA, USA

Employee

3,221

Next Earnings Date

null

Latest SEC Filings

SEC

BMRN's Discussions on X

Market Cap

Revenue

Net Income

Cash Flow

EPS

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-15-26	Resumed	UBS	Buy
Oct-12-26	Upgrade	Raymond James	Outperform → Strong Buy
Aug-19-26	Initiated	BMO Capital Markets	Outperform
May-19-26	Initiated	Citigroup	Buy
May-11-26	Resumed	Goldman	Neutral
Apr-27-26	Resumed	Morgan Stanley	Overweight
Jan-28-26	Resumed	Barclays	Overweight
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Nov-06-25	Downgrade	Stifel	Buy → Hold
Sep-08-25	Initiated	H.C. Wainwright	Neutral
Sep-03-25	Initiated	Raymond James	Outperform
Jul-03-25	Resumed	Morgan Stanley	Overweight
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-24	Initiated	Evercore ISI	Outperform
Nov-15-23	Initiated	Wells Fargo	Overweight
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Bernstein	Underperform
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral
Jan-30-23	Initiated	BMO Capital Markets	Market Perform
Jan-18-23	Initiated	Canaccord Genuity	Hold
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight
Jun-13-22	Resumed	Wedbush	Neutral
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy
Sep-09-21	Upgrade	Stifel	Hold → Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-04-21	Resumed	Guggenheim	Buy
Mar-01-21	Upgrade	Evercore ISI	In-line → Outperform
Aug-20-20	Downgrade	Citigroup	Buy → Neutral
Aug-20-20	Downgrade	William Blair	Outperform → Mkt Perform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Aug-19-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-19-20	Downgrade	Stifel	Buy → Hold
Jul-08-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-06-20	Reiterated	Citigroup	Buy
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Jan-24-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-27-19	Upgrade	Barclays	Equal Weight → Overweight
Nov-12-19	Initiated	SunTrust	Buy
Oct-17-19	Resumed	BofA/Merrill	Buy
May-23-19	Resumed	Citigroup	Buy
Apr-09-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-14-18	Initiated	Wolfe Research	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-07-18	Reiterated	Stifel	Buy
Aug-03-18	Reiterated	Stifel	Buy

Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	3,221.25	2,853.92	2,419.23	2,096.04	1,846.28
Cost of revenue USD (M)	717.44	580.24	514.85	483.67	470.52
Gross profit USD (M)	-	-	1,904.37	1,612.37	1,375.76
Research and development USD (M)	921.93	747.18	746.77	649.61	628.79
Operating expenses USD (M)	2,811.78	2,369.70	1,746.28	1,462.81	1,458.10
Operating income USD (M)	409.48	484.21	158.10	149.56	-82.34
Income before tax USD (M)	482.48	541.76	188.56	149.58	-75.35
Income tax expense USD (M)	133.58	114.90	20.92	8.02	-11.27
Net income USD (M)	348.90	426.86	167.65	141.56	-64.08
Basic EPS USD/shares	1.82	2.25	0.89	0.76	-0.35
Diluted EPS USD/shares	1.80	2.21	0.87	0.75	-0.35
Basic weighted shares shares (M)	191.79	190.03	187.83	185.27	182.85
Diluted weighted shares shares (M)	197.39	196.71	191.60	188.96	182.85
Selling, general and administrative USD (M)	1,153.02	1,009.03	937.29	854.01	759.38

Biomarin Pharmaceutical Inc Stock (BMRN) Insider Trading

Davis George EricSep 02 '26
Officer
Transaction
Proposed Sale
Cost
$66.28
#Shares
17,557
Value ($)
1,163,756
#Shares Total
0
Davis George EricSep 02 '26
EVP, Chief Legal Officer
Transaction
Sale
Cost
$66.28
#Shares
17,557
Value ($)
1,163,748
#Shares Total
61,003
Friberg Gregory RMay 07 '26
EVP, Chief R&D Officer
Transaction
Sale
Cost
$53.85
#Shares
3,281
Value ($)
176,682
#Shares Total
51,818
Friberg Gregory RMay 07 '26
Officer
Transaction
Proposed Sale
Cost
$53.85
#Shares
3,281
Value ($)
176,682
#Shares Total
0
Guyer Charles GregMar 11 '26
Officer
Transaction
Proposed Sale
Cost
$60.46
#Shares
16,486
Value ($)
996,749
#Shares Total
0
Guyer Charles GregMar 11 '26
EVP, Chief Technical Officer
Transaction
Sale
Cost
$60.46
#Shares
16,486
Value ($)
996,744
#Shares Total
79,953
Friberg Gregory RFeb 26 '26
EVP, Chief R&D Officer
Transaction
Sale
Cost
$60.38
#Shares
6,326
Value ($)
381,937
#Shares Total
37,578
Davis George EricFeb 26 '26
EVP, Chief Legal Officer
Transaction
Sale
Cost
$61.36
#Shares
26,061
Value ($)
1,599,103
#Shares Total
72,453
Friberg Gregory RFeb 26 '26
Officer
Transaction
Proposed Sale
Cost
$60.38
#Shares
6,326
Value ($)
381,937
#Shares Total
0
Davis George EricFeb 26 '26
Officer
Transaction
Proposed Sale
Cost
$61.36
#Shares
26,061
Value ($)
1,599,103
#Shares Total
0

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Davis George Eric	Officer	Sep 02 '26	Proposed Sale	$66.28	17,557	1,163,756	0
Davis George Eric	EVP, Chief Legal Officer	Sep 02 '26	Sale	$66.28	17,557	1,163,748	61,003
Friberg Gregory R	EVP, Chief R&D Officer	May 07 '26	Sale	$53.85	3,281	176,682	51,818
Friberg Gregory R	Officer	May 07 '26	Proposed Sale	$53.85	3,281	176,682	0
Guyer Charles Greg	Officer	Mar 11 '26	Proposed Sale	$60.46	16,486	996,749	0
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 11 '26	Sale	$60.46	16,486	996,744	79,953
Friberg Gregory R	EVP, Chief R&D Officer	Feb 26 '26	Sale	$60.38	6,326	381,937	37,578
Davis George Eric	EVP, Chief Legal Officer	Feb 26 '26	Sale	$61.36	26,061	1,599,103	72,453
Friberg Gregory R	Officer	Feb 26 '26	Proposed Sale	$60.38	6,326	381,937	0
Davis George Eric	Officer	Feb 26 '26	Proposed Sale	$61.36	26,061	1,599,103	0

Biomarin Pharmaceutical Inc Stock (BMRN) Latest News

Nov 03, 2026

Oppenheimer maintains BioMarin Pharmaceutical at Outperform, lowers price target to $94 from $97 - TradingView

Nov 03, 2026

Cantor Fitzgerald reiterates Overweight on BioMarin stock at $86 By Investing.com - Investing.com Canada

Nov 03, 2026

BioMarin reports Q3 revenue beat but cuts full-year outlook - Investing.com

Nov 03, 2026

Oppenheimer lowers BioMarin stock price target to $94 on guidance cut - Investing.com Canada

Nov 03, 2026

Stifel cuts BioMarin stock price target to $66 on growth concerns - Investing.com

Nov 03, 2026

Nov 02, 2026

BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut - Yahoo Finance Australia

Nov 02, 2026

BioMarin (BMRN) Stock May Be A Bargain After Fabry Therapy Deal - Yahoo Finance Singapore

Nov 02, 2026

Form 8K Biomarin Pharmaceutical Inc For: 2 November By Investing.com - Investing.com Nigeria

Nov 02, 2026

Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript - Benzinga

Nov 02, 2026

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research

Nov 02, 2026

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates - Zacks Investment Research

Nov 02, 2026

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates - Yahoo Finance UK

Nov 02, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations - Barchart.com

Nov 02, 2026

BioMarin Reports Third Quarter 2026 Financial and Operating Results - PR Newswire

Nov 02, 2026

Nov 01, 2026

BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect - Barchart.com

Nov 01, 2026

Oct 30, 2026

GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin - KED Global

Oct 30, 2026

Oct 29, 2026

GC Biopharma, Hanmi Pharmaceutical License Fabry Disease Drug to BioMarin for approximately $478 Million - BigGo Finance

Oct 29, 2026

BioMarin inks license agreement for Fabry disease therapy - The Pharma Letter

Oct 29, 2026

BioMarin, GC Biopharma, Hanmi Pharm to Collaborate on Fabry Disease Treatment - Contract Pharma

Oct 29, 2026

BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug - MedCity News

Oct 29, 2026